

Company

Mitsubishi UFJ Capital Co.,Ltd.

Presenter

Mikihiko Shinozaki



Life Science Fund

-Fund for bridging ideas into practical use at seed stage in life science fields-



OiDE[®] Fund

-Joint fund with Daiichi Sankyo to target fields of ground breaking drug discovery-

Mitsubishi UFJ Life Science I, Limited Partnership

Summary	<ul style="list-style-type: none"> ■ Fund Size : ¥10 Billion ■ Fund Term : 12 years (Feb. 2017- 2029) ■ Seeds, Early, Middle up to Late Stage Investments ■ Cross Boarder Investment : Less than 20% of Total Fund Commitment
Focus Area	<ul style="list-style-type: none"> ■ Discovery and Development of Novel Therapeutics ■ Regenerative Medicine ■ Medical Device ■ Diagnostic medicine and Diagnostic Device
Investment Size	<ul style="list-style-type: none"> ■ ¥ 100-500 Million per company

OiDE Fund

Summary	<ul style="list-style-type: none"> ■ Fund Size : ¥1 Billion ■ Fund Term : 10 years (Sep. 2013- 2023) ■ This fund helps to nurture promising research findings and outcomes into groundbreaking basic technologies for drug discovery from the perspective of pharmaceutical companies
Focus Area	<ul style="list-style-type: none"> ■ Basic technologies for drug discovery excluding low molecular weight compounds ■ Regenerative Medicine
Investment Size	<ul style="list-style-type: none"> ■ ¥ -200 Million per project

Disclaimer

This presentation has been prepared by Mitsubishi UFJ Capital Co., Ltd. (MUCAP) for information purposes only. It is not an offer or solicitation for the purchase or sale of any financial instrument. Reasonable care has been taken to ensure that the information contained herein is not untrue or misleading, but no representation is made as to its accuracy or completeness.

Copyrights to the contents of this document are owned by MUCAP. They may not be used, copied or altered without the prior express consent of MUCAP.